Search for other papers by Rosalie Cabry in
Google Scholar
PubMed
Search for other papers by Philippe Merviel in
Google Scholar
PubMed
Search for other papers by Aicha Madkour in
Google Scholar
PubMed
Search for other papers by Elodie Lefranc in
Google Scholar
PubMed
Search for other papers by Florence Scheffler in
Google Scholar
PubMed
Search for other papers by Rachel Desailloud in
Google Scholar
PubMed
Search for other papers by Véronique Bach in
Google Scholar
PubMed
Search for other papers by Moncef Benkhalifa in
Google Scholar
PubMed
female fertility, oocyte-embryo quality, and clinical outcomes in IVF programmes. Pesticides as EDCs A large body of evidence from animal studies and epidemiological surveys shows that pesticides like bisphenol A (BPA) and phthalates have an
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Prishila Fookeerah in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Winny Varikatt in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Meena Shingde in
Google Scholar
PubMed
Department of Neurosurgery, Westmead Hospital, Sydney, Australia
Search for other papers by Mark A J Dexter in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Mark McLean in
Google Scholar
PubMed
which lack fidelity to a single differentiation pathway ( 3 ). Importantly, the long-term clinical outcomes of this relatively new PitNET subtype are not known. In this paper, we describe the histological, clinical and prognostic features of multilineage
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
Search for other papers by Anna C van der Burgh in
Google Scholar
PubMed
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
Search for other papers by Samer R Khan in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Ewout J Hoorn in
Google Scholar
PubMed
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
Search for other papers by Layal Chaker in
Google Scholar
PubMed
decline is positive or negative ( 19 , 20 , 21 , 22 ). Prior studies assessing the association between serum testosterone and kidney function in the general population as well as the association between serum testosterone and clinical outcomes in a
Search for other papers by Joana Simões-Pereira in
Google Scholar
PubMed
Search for other papers by Daniel Macedo in
Google Scholar
PubMed
Search for other papers by Maria João Bugalho in
Google Scholar
PubMed
inflammatory process related with RAI. We aimed to characterize a series of 27 patients with CNS metastases from thyroid cancer in terms of demography, histological features of the primary tumor, diagnostic approach, treatment modalities and clinical outcomes
Search for other papers by A Al-Sharefi in
Google Scholar
PubMed
Search for other papers by P Perros in
Google Scholar
PubMed
Search for other papers by R A James in
Google Scholar
PubMed
Introduction
Phaeochromocytomas/paragangliomas (PHAEO/PG) are linked to hereditary syndromes including Neurofibromatosis type 1 (NF-1). Current guidelines do not recommend biochemical screening for PHAEO/PG in asymptomatic or normotensive patients with NF-1. This strategy may miss preventable morbidities in those patients who ultimately present with symptomatic PHAEO/PG. Our aim was to review the literature and extract data on mode of presentation and the incidence of reported adverse outcomes.
Methods
PubMed and EMBASE literature search using the keywords ‘Phaeochromocytoma’, ‘Paraganglioma’ and ‘Neurofibromatosis’ was performed looking for reported cases from 2000 to 2018.
Results
Seventy-three reports of NF-1 patients with PHAEO/PG were found. Patients were predominately women (n = 40) with a median age of 46 years (range 16–82). PHAEO/PG was found incidentally in most patients, 36/73 did not present with typical symptoms while 27 patients were normotensive at diagnosis. Thirty-one patients had adverse outcomes including metastases and death.
Conclusion
Given the protean presentation of PHAEO/PG, relying on symptomology and blood pressure status as triggers for screening, is associated with adverse outcomes. Further studies are required to ascertain whether biochemical screening in asymptomatic and normotensive patients with NF-1 can reduce the rate of adverse outcomes.
Search for other papers by Xinge Tao in
Google Scholar
PubMed
Search for other papers by Yanbin Xue in
Google Scholar
PubMed
Search for other papers by Rui Niu in
Google Scholar
PubMed
Search for other papers by Wenjing Lu in
Google Scholar
PubMed
Search for other papers by Huayan Yao in
Google Scholar
PubMed
Search for other papers by Chunmei He in
Google Scholar
PubMed
Search for other papers by Bin Cui in
Google Scholar
PubMed
Xiamen Key Laboratory for Clinical Efficacy and Evidence-Based Research of Traditional Chinese Medicine, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
Fujian Province Key Laboratory of Diabetes Translational Medicine, The First Affiliated Hospital of Xiamen University, School of medicine, Xiamen University, Xiamen, China
Search for other papers by Changqin Liu in
Google Scholar
PubMed
Objective
The aim of this study was to compare the differences in incident population, comorbidities, and glucose-lowering drug prescriptions between newly diagnosed patients with early-onset type 2 diabetes mellitus (T2DM) and those with late-onset T2DM to provide real-world evidence for clinical practice.
Methods
This study was based on the Shanghai Hospital Link Database (SHLD). Anonymized electronic medical record (EHR) data from 2013 to 2021 were included in this study. Newly diagnosed patients with T2DM were defined as those without related diagnostic records or glucose-lowering medicine prescriptions in the past 3 years. Early-onset T2DM was defined as patients who were aged 18–40 years old at the first visit for T2DM to represent those who were born after the 1980s. And late-onset T2DM was defined as those aged 65–80 years old to represent those who were born in a relatively undeveloped period. Descriptive statistical analyses were performed to describe their incidence number, glucose-lowering drug prescriptions, and comorbidities at the first visit to the hospital between two T2DM groups.
Results
There were a total of 35,457 newly diagnosed patients with early-onset T2DM and 149,108 newly diagnosed patients with late-onset T2DM included in this study. Patients with late-onset T2DM constituted the majority and their number increased by 2.5% on average by years, while the number of patients with early-onset T2DM remained stable each year. Compared with late-onset T2DM patients, more early-onset T2DM patients had dyslipidemia at the first visit to hospitals (9.5% vs 7.7%, P < 0.01) despite their significant age differences. Patients with early-onset T2DM were more likely to use metformin (74.8% vs 46.5, P < 0.01), dipeptidyl peptidase-4 inhibitors (DDP-4i) (16.7% vs 11.2%, P < 0.01), thiazolidinediones (TZD) (14.9% vs 8.4%, P < 0.01), sodium glucose cotransporter 2 inhibitors (SGLT2-i) (0.8% vs 0.3%, P < 0.01), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) (3.7% vs 0.5%, P < 0.01) at their first visit to the hospital.
Conclusions
Different characteristics were observed between patients with early-onset T2DM and those with late-onset T2DM. Compared with patients with late-onset T2DM, those with early-onset T2DM were more prone to dyslipidemia and had novel organ-protective drugs prescribed.
Search for other papers by Danuta Gąsior-Perczak in
Google Scholar
PubMed
Search for other papers by Iwona Pałyga in
Google Scholar
PubMed
Search for other papers by Monika Szymonek in
Google Scholar
PubMed
Search for other papers by Artur Kowalik in
Google Scholar
PubMed
Search for other papers by Agnieszka Walczyk in
Google Scholar
PubMed
Search for other papers by Janusz Kopczyński in
Google Scholar
PubMed
Search for other papers by Katarzyna Lizis-Kolus in
Google Scholar
PubMed
Search for other papers by Anna Słuszniak in
Google Scholar
PubMed
Search for other papers by Janusz Słuszniak in
Google Scholar
PubMed
Search for other papers by Tomasz Łopatyński in
Google Scholar
PubMed
Search for other papers by Ryszard Mężyk in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Stanisław Góźdź in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Aldona Kowalska in
Google Scholar
PubMed
patients at high risk of unfavorable clinical outcomes. Two systems for the early assessment of risk are currently used in clinical practice: a system adopted by the American Thyroid Association (ATA) and a slightly different system adopted by the European
Radboud Institute for Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Thomas Crezee in
Google Scholar
PubMed
Search for other papers by Mirela Petrulea in
Google Scholar
PubMed
Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Doina Piciu in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Search for other papers by Jan W A Smit in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Theo S Plantinga in
Google Scholar
PubMed
Endocrinology Clinic, Cluj County Emergency Hospital, Cluj-Napoca, Romania
Search for other papers by Carmen E Georgescu in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Tumors, Institute of Oncology ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
mTOR in the pathogenesis and clinical outcome of NMTC has not been studied so far. For the present study, we therefore hypothesized that PI3K, Akt and mTOR germline variants influence tumorigenesis and progression of NMTC in a similar fashion as
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Search for other papers by Woo Kyung Lee in
Google Scholar
PubMed
Search for other papers by Mi-Hyeon You in
Google Scholar
PubMed
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Sheue-yann Cheng in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Yu-Mi Lee in
Google Scholar
PubMed
from the GSEA, those with a nominal P- value < 0.05 and a false discovery rate (FDR) q-value < 0.10 were considered statistically significant. For clinical outcomes, tumor-node-metastasis (TNM) stages, according to the 6thAmerican Joint Committee on
Search for other papers by Ali Abbara in
Google Scholar
PubMed
Search for other papers by Sophie Clarke in
Google Scholar
PubMed
Search for other papers by Pei Chia Eng in
Google Scholar
PubMed
Search for other papers by James Milburn in
Google Scholar
PubMed
Search for other papers by Devavrata Joshi in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Alexander N Comninos in
Google Scholar
PubMed
Search for other papers by Rozana Ramli in
Google Scholar
PubMed
Search for other papers by Amrish Mehta in
Google Scholar
PubMed
Search for other papers by Brynmor Jones in
Google Scholar
PubMed
Search for other papers by Florian Wernig in
Google Scholar
PubMed
Search for other papers by Ramesh Nair in
Google Scholar
PubMed
Search for other papers by Nigel Mendoza in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Amir H Sam in
Google Scholar
PubMed
Search for other papers by Emma Hatfield in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Waljit S Dhillo in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Niamh M Martin in
Google Scholar
PubMed
, predisposing factors and the clinical outcomes. Materials and methods We retrospectively reviewed clinical records of all patients who presented to Imperial College NHS Healthcare Trust with pituitary apoplexy during the period 1991 to 2015. We
